Literature DB >> 1456752

Photodynamic therapy for the treatment of basal cell carcinoma.

B D Wilson1, T S Mang, H Stoll, C Jones, M Cooper, T J Dougherty.   

Abstract

BACKGROUND: Photodynamic therapy is an investigational method for the treatment of a variety of solid tumors. The purpose of this study was to determine the optimum factors and illustrate the effectiveness of photodynamic therapy in the treatment of basal cell carcinomas. This was a prospective study in which patients presenting with primary or recurrent basal cell tumors, particularly but not exclusively widespread tumors or large single tumors, were offered the option of photodynamic therapy in their treatment regimen.
RESULTS: Patients were administered 1 mg/kg of a photosensitizer (Photofrin II). Light doses (630 nm) ranged from 72 to 288 J/cm2. A total of 37 patients with 151 sites were treated in this study. A complete response rate of 88% was achieved with one application. Morbidity was low; the most significant side effects were moderate pain and edema.
CONCLUSIONS: Photodynamic therapy is a modality that offers localized treatment of primary or recurrent nonmelanoma skin cancer. By applying reciprocal doses of photosensitizer and light, the efficacy of photodynamic therapy in the treatment of skin lesions is demonstrated achieving significant light penetration into tissue with a high complete response rate of the lesions and acceptable normal tissue response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1456752

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  20 in total

1.  Long-term results after surgical basal cell carcinoma excision in the eyelid region.

Authors:  S Pieh; A Kuchar; P Novak; R Kunstfeld; G Nagel; F J Steinkogler
Journal:  Br J Ophthalmol       Date:  1999-01       Impact factor: 4.638

Review 2.  Photodynamic therapy in head and neck cancer.

Authors:  Merrill A Biel
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.075

3.  Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy.

Authors:  C J Dimitroff; W Klohs; A Sharma; P Pera; D Driscoll; J Veith; R Steinkampf; M Schroeder; S Klutchko; A Sumlin; B Henderson; T J Dougherty; R J Bernacki
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

4. 

Authors:  C S Betz; A Leunig
Journal:  HNO       Date:  2004-02       Impact factor: 1.284

5.  Determination of tissue optical properties in PDT treated Head & Neck patients.

Authors:  Andreea Dimofte; Jarod C Finlay; Anna V Sharikova; Keith A Cengel; Peter Ahn; Theresa M Busch; Timothy C Zhu
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2014-02-01

Review 6.  Photodynamic therapy in the treatment of cancer: current state of the art.

Authors:  R A Hsi; D I Rosenthal; E Glatstein
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

7.  [Advanced carcinoma of the eyelids. Principles of plastic reconstruction after excision].

Authors:  N Sivkova
Journal:  Ophthalmologe       Date:  2005-06       Impact factor: 1.059

8.  Small margin excision of periocular basal cell carcinoma: 5 year results.

Authors:  J D Hsuan; R A Harrad; M J Potts; C Collins
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

9.  Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment.

Authors:  A Martin; W D Tope; J M Grevelink; J C Starr; J L Fewkes; T J Flotte; T F Deutsch; R R Anderson
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

Review 10.  Pharmacological treatments for basal cell carcinoma.

Authors:  Seongmu Lee; Dinesh Selva; Shyamala C Huilgol; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.